Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  DexCom, Inc.    DXCM

DEXCOM, INC.

(DXCM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Dexcom : G6® CGM System Now Available In Canada

share with twitter share with LinkedIn share with facebook
share via e-mail
02/17/2020 | 05:31am EDT

DexCom Inc., a leader in continuous glucose monitoring (CGM), announced today that it is now accepting orders for the Dexcom G6 CGM System for people with diabetes ages two years and up.

"We are thrilled to offer the Dexcom G6 Continuous Glucose Monitoring (CGM) System to Canadians and are proud of this innovative technology that enables more effective diabetes management," said Laura Endres, Vice President and General Manager, Dexcom Canada, Inc. "The Dexcom G6 not only frees people with diabetes from the burden of fingersticks, but also offers real-time alerts and other features that can help people make more informed decisions for their daily diabetes management. This product changes people's lives."

The Dexcom G6 is now available and builds upon the core attributes of the Dexcom G5 Mobile CGM technology platform, while introducing new features that empower users to take control of their diabetes:

Elimination of fingersticks for calibration and diabetes treatment decisions*

Continuous glucose readings sent automatically using Bluetooth technology to any compatible smart device+, or to a Dexcom receiver, at five-minute intervals

Customizable alerts and alarms, including a new Urgent Low Soon alert which can warn users up to 20 minutes in advance of an urgent hypoglycemic event, so they can take steps to prevent it

Real-time data sharing with the Dexcom G6 app, allowing the user to share their glucose data with up to five followers to monitor their glucose levels remotely for extra peace of mind

10-day sensor allowing for longer wear (3 days longer than the previous generation Dexcom CGM)

A slimmer transmitter with a lower profile for more discreet wear ability

An auto-applicator designed to make sensor insertion simple with the touch of a button

A newly designed receiver with a touchscreen display (optional display device)

New sensor membrane that enables acetaminophen use without any effect on glucose readings?

"It is an exciting time for diabetes management, as new advancements in diabetes monitoring technology allow patients to move away from the traditional fingerstick blood glucose monitoring to continuous blood glucose monitoring" said Dr. Remi Rabasa-Lhoret, Endocrinologist & Director of the Montreal Clinical Research Institute Diabetes Clinic. "Rather than multiple daily checks, patients can now have access to real-time detailed blood glucose profiles with alarms, allowing them to prevent and treat both low and high blood glucose levels - enabling easier and more informed therapeutic decisions. These devices are key to achieve recommended therapeutic goals more safely and easily. The Dexcom G6 is another advancement for glucose monitoring - allowing 10 days of wireless glucose monitoring without fingersticks, using an accurate, small and easy to use device."

In Canada, both current and new CGM users can now purchase a Dexcom G6 CGM starter kit at the Dexcom Store online at www.dexcom.com

More information on Dexcom G6 can be found at www.dexcom.com.

*If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

+To view a list of compatible devices, visit www.dexcom.com/compatibility

? G6 readings can be used to make diabetes treatment decisions when taking up to a maximum acetaminophen dose of 1,000mg every six hours. Taking a higher dose may affect the G6 readings.

.

(C) 2020 M2 COMMUNICATIONS, source M2 PressWIRE

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on DEXCOM, INC.
04/02DEXCOM SCHEDULES FIRST QUARTER 2020 : 30 p.m. Eastern Time
BU
03/30QUALCOMM : Names Heather Ace as Executive Vice President of Human Resources; Exe..
AQ
03/10DEXCOM INC : Change in Directors or Principal Officers (form 8-K)
AQ
03/06How Lipper Award-winning fund managers are playing coronavirus scare
RE
02/24DEXCOM : to Present at Cowen 40th Annual Healthcare Conference
BU
02/20DEXCOM : G6 Continuous Glucose Monitoring (CGM) System Receives CE Mark for Use ..
BU
02/17DEXCOM : G6® CGM System Now Available In Canada
AQ
02/17DEXCOM : and Companion Medical Announce Collaboration to Integrate Dexcom CGM Da..
AQ
02/17DEXCOM : Announces FDA Clearance of New Dexcom G6 Pro CGM
AQ
02/13DEXCOM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
More news
Financials (USD)
Sales 2020 1 750 M
EBIT 2020 227 M
Net income 2020 166 M
Finance 2020 4,07 M
Yield 2020 -
P/E ratio 2020 159x
P/E ratio 2021 98,7x
EV / Sales2020 13,9x
EV / Sales2021 11,2x
Capitalization 24 399 M
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | DXCM | US2521311074 | MarketScreener
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 284,32  $
Last Close Price 266,38  $
Spread / Highest target 23,9%
Spread / Average Target 6,73%
Spread / Lowest Target -30,6%
EPS Revisions
Managers
NameTitle
Kevin Ronald Sayer Chairman, President & Chief Executive Officer
Quentin S. Blackford Chief Operating & Financial Officer
Andrew K. Balo EVP-Clinical Affairs, Regulatory Strategies
Jacob Leach Chief Technology Officer
Jay S. Skyler Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DEXCOM, INC.19.21%24 664
MEDTRONIC PLC-23.96%120 856
BAXTER INTERNATIONAL INC.-2.63%41 180
HOYA CORPORATION-5.74%32 156
TERUMO CORPORATION-3.23%25 993
ZIMMER BIOMET HOLDINGS-38.53%20 891